A Study of a Weight Loss Intervention in People With Endometrial Cancer

NCT06751589 · Recruiting

Last updated 2026-05-28

This clinical trial is testing a weight loss program in people who have endometrial cancer to see how many complete the treatment.

Status Recruiting Currently enrolling participants.

Phase Early Phase 1 First exploratory testing in people.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 36 people Planned (estimated).

Who can join Ages 18+ · female only

Timeline Started 2024-12 · est. completion 2027-12

Where 7 sites · United States

What this study is testing ClinicalTrials.gov NCT06751589 ↗

Description as written by the study sponsor.

The researchers are doing this study is to find out whether tirzepatide and semaglutide are practical (feasible) for weight management and blood sugar control for endometrial cancer patients undergoing chemotherapy. The researchers will also look at participants' experience with the study drug, the safety of taking the study drug while receiving chemotherapy, and changes in weight, body fat composition, and blood pressure of participants.

Treatments tested

Tirzepatide Drug

2.5 mg administered using a pre-filled injector once weekly for 4 weeks and then increase to 5 mg once weekly.

Main thing measured	percentage of patients that complete treatment
Sponsor	Memorial Sloan Kettering Cancer Center
Conditions studied	Endometrial Cancer
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06751589 ↗